VEA
TVRD

Virtus ETF Advisers’s Tvardi Therapeutics TVRD Stock Holding History

Virtus ETF Advisers’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-241
Closed -$42.5K – 487
2023
Q1 		$42.5K Sell
241
-92
-28% -$30.8K 0.02% 434
2022
Q4 		$129K Sell
333
-39
-10% -$14.8K 0.07% 394
2022
Q3 		$125K Buy
372
+3
+0.8% +$1.09K 0.05% 387
2022
Q2 		$121K Buy
369
+10
+3% +$3.51K 0.04% 382
2022
Q1 		$157K Sell
359
-22
-6% -$9.03K 0.07% 220
2021
Q4 		$167K Sell
381
-30
-7% -$15.1K 0.06% 303
2021
Q3 		$229K Sell
411
-22
-5% -$11K 0.1% 233
2021
Q2 		$222K Sell
433
-127
-23% -$80.5K 0.09% 269
2021
Q1 		$437K Buy
560
+10
+2% +$6.85K 0.18% 166
2020
Q4 		$300K Sell
550
-19
-3% -$9.96K 0.12% 212
2020
Q3 		$261K Sell
569
-78
-12% -$45.3K 0.14% 252
2020
Q2 		$398K Buy
647
+44
+7% +$24.3K 0.19% 198
2020
Q1 		$287K Sell
603
-88
-13% -$47.8K 0.12% 228
2019
Q4 		$401K Buy
691
+329
+91% +$231K 0.07% 253
2019
Q3 		$238K Sell
362
-21
-5% -$17.5K 0.05% 221
2019
Q2 		$296K Buy
+383
New +$269K 0.06% 224
2019
Q1 		– Sell
-594
Closed -$278K – 272
2018
Q4 		$278K Sell
594
-190
-24% -$123K 0.05% 137
2018
Q3 		$676K Sell
784
-561
-42% -$405K 0.07% 80
2018
Q2 		$927K Sell
1,345
-304
-18% -$155K 0.82% 12
2018
Q1 		$735K Buy
1,649
+881
+115% +$427K 0.64% 90
2017
Q4 		$338K Buy
768
+243
+46% +$111K 0.42% 106
2017
Q3 		$259K Buy
525
+48
+10% +$24K 0.03% 138
2017
Q2 		$264K Sell
477
-423
-47% -$268K 0.04% 139
2017
Q1 		$596K Buy
900
+86
+11% +$45.9K 0.11% 98
2016
Q4 		$272K Buy
+814
New +$261K 0.08% 119
2016
Q2 		– Sell
-452
Closed -$101K – 150
2016
Q1 		$101K Sell
452
-29
-6% -$8.66K 0.14% 144
2015
Q4 		$292K Buy
+481
New +$264K 0.8% 38

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus ETF Advisers's TVRD Position: Q2 2023 in Review

Virtus ETF Advisers sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 241 shares — an estimated $42.5K sold.

Virtus ETF Advisers first reported a position in TVRD in Q4 2015 and held it in 27 quarters. The position peaked at $927K in Q2 2018. 136 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

  • Virtus ETF Advisers reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 241 Tvardi Therapeutics shares in Q2 2023, an estimated $42.5K.
  • Virtus ETF Advisers first reported a position in Tvardi Therapeutics in Q4 2015 and held it in 27 quarters.
  • Virtus ETF Advisers's Tvardi Therapeutics position peaked at $927K in Q2 2018.
  • 136 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.